Drugs / strontium-89
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT00156884 | Aug 2003 → May 2008 | hormone-resistant prostate carcinoma, metastatic carcinoma in the bone | Alberta Health services | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT00024167 | Apr 2002 → Sep 2014 | prostate cancer | M.D. Anderson Cancer Center | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | strontium-89 | “a dose of strontium-89” PMID 16258090 ↗ Nov 2005 |
| Modality | Other / unclassified | “Radioactive substances such as strontium-89 may relieve bone pain associated with prostate cancer” NCT00024167 ↗ |
| Route | Intravenous | “strontium chloride Sr 89 IV once at the beginning of chemotherapy” NCT00024167 ↗ |